Phirin Sam

Array ( [id] => 11312000 [patent_doc_number] => 20160348111 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'ANTISENSE DESIGN' [patent_app_type] => utility [patent_app_number] => 15/237307 [patent_app_country] => US [patent_app_date] => 2016-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 19516 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15237307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16168186 [patent_doc_number] => 10709726 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-14 [patent_title] => Connexin 45 inhibition for therapy [patent_app_type] => utility [patent_app_number] => 15/751802 [patent_app_country] => US [patent_app_date] => 2016-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 15 [patent_no_of_words] => 19317 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15751802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13372485 [patent_doc_number] => 20180237783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => METHODS AND COMPOSITIONS OF SHORT SMALL HAIRPIN RNAS AND MICRORNAS FOR WOUND HEALING [patent_app_type] => utility [patent_app_number] => 15/752182 [patent_app_country] => US [patent_app_date] => 2016-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32189 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15752182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16459484 [patent_doc_number] => 10842812 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders [patent_app_type] => utility [patent_app_number] => 15/751585 [patent_app_country] => US [patent_app_date] => 2016-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 33 [patent_no_of_words] => 22546 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15751585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13383789 [patent_doc_number] => 20180243436 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => THERAPEUTIC CELL INTERNALIZING CONJUGATES [patent_app_type] => utility [patent_app_number] => 15/750818 [patent_app_country] => US [patent_app_date] => 2016-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24560 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -57 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15750818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11419692 [patent_doc_number] => 20170027837 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'RNA COMPLEXES THAT INHIBIT MELANIN PRODUCTION' [patent_app_type] => utility [patent_app_number] => 15/220767 [patent_app_country] => US [patent_app_date] => 2016-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 14921 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15220767 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12254423 [patent_doc_number] => 09926561 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-27 [patent_title] => 'Composition for regenerating normal tissue from fibrotic tissue' [patent_app_type] => utility [patent_app_number] => 15/208440 [patent_app_country] => US [patent_app_date] => 2016-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 23 [patent_no_of_words] => 14298 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15208440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11107908 [patent_doc_number] => 20160304879 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'Double-Stranded RNA Compounds to CASP2 and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 15/200544 [patent_app_country] => US [patent_app_date] => 2016-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 16489 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15200544 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12880966 [patent_doc_number] => 20180185497 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/740914 [patent_app_country] => US [patent_app_date] => 2016-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32871 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15740914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11737392 [patent_doc_number] => 09701967 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-07-11 [patent_title] => 'Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions' [patent_app_type] => utility [patent_app_number] => 15/189159 [patent_app_country] => US [patent_app_date] => 2016-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 61 [patent_no_of_words] => 66510 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15189159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11336935 [patent_doc_number] => 20160362690 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-15 [patent_title] => 'NOVEL POLYNUCLEOTIDES AND METHODS FOR INHIBITING CANCER CELLS' [patent_app_type] => utility [patent_app_number] => 15/179565 [patent_app_country] => US [patent_app_date] => 2016-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 7940 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15179565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12773473 [patent_doc_number] => 20180149659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-31 [patent_title] => DIAGNOSIS AND TREATMENT OF MERS-RELATED RENAL DISEASE [patent_app_type] => utility [patent_app_number] => 15/579528 [patent_app_country] => US [patent_app_date] => 2016-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10558 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15579528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11061001 [patent_doc_number] => 20160257963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-08 [patent_title] => 'RNAi-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONS' [patent_app_type] => utility [patent_app_number] => 15/156430 [patent_app_country] => US [patent_app_date] => 2016-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 11940 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15156430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15163687 [patent_doc_number] => 10487325 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-26 [patent_title] => GATA-3 inhibitors for use in the treatment of Th2-driven asthma [patent_app_type] => utility [patent_app_number] => 15/574345 [patent_app_country] => US [patent_app_date] => 2016-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 12 [patent_no_of_words] => 14135 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15574345 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14535169 [patent_doc_number] => 20190203206 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => COMPOSITIONS AND METHODS FOR CONTROLLING ARTHROPOD PARASITE AND PEST INFESTATIONS [patent_app_type] => utility [patent_app_number] => 15/571697 [patent_app_country] => US [patent_app_date] => 2016-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39438 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15571697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11099580 [patent_doc_number] => 20160296550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-13 [patent_title] => 'Methods for Treating or Preventing Ophthalmological Conditions' [patent_app_type] => utility [patent_app_number] => 15/144429 [patent_app_country] => US [patent_app_date] => 2016-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 41159 [patent_no_of_claims] => 107 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15144429 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13522603 [patent_doc_number] => 20180312844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => TREATMENT FOR CANCER METASTASIS [patent_app_type] => utility [patent_app_number] => 15/566048 [patent_app_country] => US [patent_app_date] => 2016-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22169 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15566048 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12017124 [patent_doc_number] => 09809817 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-07 [patent_title] => 'Oligonucleotide compounds for targeting huntingtin mRNA' [patent_app_type] => utility [patent_app_number] => 15/089319 [patent_app_country] => US [patent_app_date] => 2016-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 146 [patent_figures_cnt] => 162 [patent_no_of_words] => 54569 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15089319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12106483 [patent_doc_number] => 09862952 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-09 [patent_title] => 'Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders' [patent_app_type] => utility [patent_app_number] => 15/089437 [patent_app_country] => US [patent_app_date] => 2016-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 59 [patent_figures_cnt] => 79 [patent_no_of_words] => 48471 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15089437 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12942532 [patent_doc_number] => 09833468 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-05 [patent_title] => Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA [patent_app_type] => utility [patent_app_number] => 15/084255 [patent_app_country] => US [patent_app_date] => 2016-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 11 [patent_no_of_words] => 31208 [patent_no_of_claims] => 51 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15084255 [rel_patent_id] =>[rel_patent_doc_number] =>)